ProCE Banner Activity

Contemporary Management of HIV: Integrating New Data From CROI 2019

Slideset Download
Download this expert-authored slideset to review key data from CROI 2019 on a wide range of HIV topics, including new approaches to PrEP, treating HIV in women and during pregnancy, INSTIs for switch/maintenance therapy, complications of HIV and/or ART, and novel therapeutic agents.

Released: May 10, 2019

Expiration: May 08, 2020

No longer available for credit.

Share

Faculty

Joseph J. Eron

Joseph J. Eron, Jr., MD

Professor of Medicine
University of North Carolina School of Medicine
Director, AIDS Clinical Trials Unit
University of North Carolina
Chapel Hill, North Carolina

Princy N. Kumar

Princy N. Kumar, MD

Professor of Medicine and Microbiology
Division of Infectious Diseases
Georgetown University Hospital
Division Chief
Division of Infectious Diseases and Travel Medicine
Department of Internal Medicine
Medstar Georgetown University Hospital
Washington, DC

Daniel R. Kuritzkes

Daniel R. Kuritzkes, 医学博士

科长,传染病科
布莱根妇女医院
Harriet Ryan Albee 医学教授
哈佛医学院
波士顿,马萨诸塞州

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

ViiV Healthcare

Program Director Disclosure

Program Director

Joseph J. Eron, Jr., MD

Professor of Medicine
University of North Carolina School of Medicine
Director, AIDS Clinical Trials Unit
University of North Carolina
Chapel Hill, North Carolina

Joseph J. Eron, Jr., MD, has disclosed that he has received consulting fees from Gilead Sciences, Janssen, Merck, and ViiV and funds for research support from Gilead Sciences, Janssen, and ViiV.

Princy N. Kumar, MD

Professor of Medicine and Microbiology
Division of Infectious Diseases
Georgetown University Hospital
Division Chief
Division of Infectious Diseases and Travel Medicine
Department of Internal Medicine
Medstar Georgetown University Hospital
Washington, DC

Princy N. Kumar, MD, has disclosed that she has received consulting fees from GlaxoSmithKline/ViiV, Janssen/Johnson & Johnson, Merck, and Theratechnologies; has received funds for research support from Gilead Sciences, GlaxoSmithKline/ViiV, Janssen/Johnson & Johnson, Merck, and Theratechnologies; and has ownership interest in Gilead Sciences, GlaxoSmithKline/ViiV, Janssen/Johnson & Johnson, and Merck.

Faculty Disclosure

Primary Author

Daniel R. Kuritzkes, 医学博士

科长,传染病科
布莱根妇女医院
Harriet Ryan Albee 医学教授
哈佛医学院
波士顿,马萨诸塞州

Daniel R. Kuritzkes, MD, has disclosed that he has received consulting fees from Abivax, Gilead Sciences, GlaxoSmithKline, Merck, and ViiV Healthcare; fees for non-CME/CE services from Janssen; and funds for research support from Abbott, Gilead Sciences, Merck, and ViiV Healthcare.